title: Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana.
abstract: OBJECTIVE
  To describe the response to highly active antiretroviral treatment (HAART) in a public sector pilot antiretroviral (ARV) treatment program in Botswana.
  
  
  METHODS
  The response to HAART is described in adult HIV-infected ARV-naive patients initiating treatment from April 2001 to January 2002 at Princess Marina Hospital in Gaborone, Botswana. Patients had medical and laboratory evaluations before initiating ARV treatment and were followed longitudinally. For analysis, data were collected from charts and patient management records.
  
  
  RESULTS
  One hundred fifty-three ARV-naive patients initiated HAART. Most received didanosine plus stavudine (ddI + d4T) with efavirenz or nevirapine. The mean CD4 cell count increase was 149 cells/mm at 24 weeks and 204 cells/mm at 48 weeks. The percentage of patients with an HIV-1 RNA level < or =400 copies/mL was 87.0% at 24 weeks and 78.8% at 48 weeks. The Kaplan-Meier 1-year survival estimate was 84.7% (79.0%, 90.8%), with a 3.2-fold increased risk (P = 0.004) of mortality among patients with a CD4 cell count <50 cells/mm. The 1-year Kaplan-Meier estimate of toxicity-related drug switches was 32.2% (20.3%, 40.4%). The most common toxicity was peripheral neuropathy, occurring more frequently in patients with a preexisting diagnosis of peripheral neuropathy and among those placed on ddI + d4T-containing regimens.
  
  
  CONCLUSIONS
  An excellent response to HAART was observed among HIV-1C-infected patients, paralleling those seen elsewhere. Despite excellent responses, high rates of toxicity were observed for ddI + d4T-containing regimens.
authors.affiliation: Botswana-Harvard School of Public Health AIDS Initiative Partnership for Research and Education, Gaborone, Botswana.
authors.forename: C William
authors.initials: CW
authors.lastname: Wester
authors.forename: Soyeon
authors.initials: S
authors.lastname: Kim
authors.forename: Hermann
authors.initials: H
authors.lastname: Bussmann
authors.forename: Ava
authors.initials: A
authors.lastname: Avalos
authors.forename: Ndwapi
authors.initials: N
authors.lastname: Ndwapi
authors.forename: Trevor F
authors.initials: TF
authors.lastname: Peter
authors.forename: Tendani
authors.initials: T
authors.lastname: Gaolathe
authors.forename: Andrew
authors.initials: A
authors.lastname: Mujugira
authors.forename: Lesego
authors.initials: L
authors.lastname: Busang
authors.forename: Chris
authors.initials: C
authors.lastname: Vanderwarker
authors.forename: Peter
authors.initials: P
authors.lastname: Cardiello
authors.forename: Onalethata
authors.initials: O
authors.lastname: Johnson
authors.forename: Ibou
authors.initials: I
authors.lastname: Thior
authors.forename: Patson
authors.initials: P
authors.lastname: Mazonde
authors.forename: Howard
authors.initials: H
authors.lastname: Moffat
authors.forename: Max
authors.initials: M
authors.lastname: Essex
authors.forename: Richard
authors.initials: R
authors.lastname: Marlink
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001902:Botswana; D018791:CD4 Lymphocyte Count; D003906:Developing Countries; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008329:Managed Care Programs; D008499:Medical Records; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D010865:Pilot Projects; D015397:Program Evaluation; D017150:Public Sector; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents